These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32667156)

  • 21. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes-Randomized controlled study.
    Oita M; Miyoshi H; Ono K; Nakamura A; Cho KY; Nomoto H; Yamamoto K; Omori K; Manda N; Kurihara Y; Aoki S; Atsumi T
    Endocr J; 2018 Feb; 65(2):141-150. PubMed ID: 29093280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic indications of incretin-related derivatives and other oral hypoglycemic agents].
    Katsuno T; Miyagawa J
    Nihon Rinsho; 2012 May; 70 Suppl 3():693-8. PubMed ID: 22768600
    [No Abstract]   [Full Text] [Related]  

  • 24. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis.
    Kadowaki T; Yamamoto F; Taneda Y; Naito Y; Clark D; Lund SS; Okamura T; Kaku K
    Expert Opin Drug Saf; 2021 Jun; 20(6):707-720. PubMed ID: 33706621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
    Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glyxambi--a new combination for type 2 diabetes.
    Med Lett Drugs Ther; 2015 Apr; 57(1467):65-6. PubMed ID: 25897551
    [No Abstract]   [Full Text] [Related]  

  • 29. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2 diabetes and metabolic syndrome.
    Sicras-Mainar A; Navarro-Artieda R
    Diabetes Technol Ther; 2014 Nov; 16(11):722-7. PubMed ID: 25089916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes.
    Rosenstock J; Sankoh S; List JF
    Diabetes Obes Metab; 2008 May; 10(5):376-86. PubMed ID: 18355324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
    Derosa G; Maffioli P
    Diabetes Technol Ther; 2012 Apr; 14(4):350-64. PubMed ID: 22324384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Saxagliptin + metformin. Mostly disadvantages.
    Prescrire Int; 2013 Feb; 22(135):40. PubMed ID: 23444500
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of dextromethorphan as add-on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo-controlled, double-blinded, multiple crossover, single-dose clinical trial.
    Marquard J; Stirban A; Schliess F; Sievers F; Welters A; Otter S; Fischer A; Wnendt S; Meissner T; Heise T; Lammert E
    Diabetes Obes Metab; 2016 Jan; 18(1):100-3. PubMed ID: 26362564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing clinical outcomes resulting from glucose-lowering therapies in type 2 diabetes: increased confidence about the DPP-4 inhibitors and continued concerns regarding sulphonylureas and exogenous insulin.
    Currie CJ; Holden SE
    Diabetes Obes Metab; 2014 Oct; 16(10):881-4. PubMed ID: 25040702
    [No Abstract]   [Full Text] [Related]  

  • 36. [Gliptin-gliflozin combination for treating type 2 diabetes].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral antidiabetic agents in type 2 diabetes.
    Levetan C
    Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Approach to diabetic therapy. 2. Selection and the use of oral antidiabetics. 3) Biguanides and alpha-glucosidase inhibitors].
    Onuma T
    Nihon Naika Gakkai Zasshi; 2000 Aug; 89(8):1536-43. PubMed ID: 11062901
    [No Abstract]   [Full Text] [Related]  

  • 39. Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.
    Prasanna Kumar KM; Phadke U; Brath H; Gawai A; Paldánius PM; Mathieu C
    Prim Care Diabetes; 2016 Dec; 10(6):452-458. PubMed ID: 27353459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of saxagliptin add-on therapy to insulin on blood glycemic fluctuations in patients with type 2 diabetes: A randomized, control, open-labeled trial.
    Li FF; Jiang LL; Yan RN; Zhu HH; Zhou PH; Zhang DF; Su XF; Wu JD; Ye L; Ma JH
    Medicine (Baltimore); 2016 Oct; 95(43):e5229. PubMed ID: 27787387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.